FOSTER CITY, Calif., June 28, 2024--Mirum Submits New Drug Application to FDA for Chenodiol for the Treatment of CTX
This biotech stock nears a buy point after an explosive move following positive drug trial news. Sales have grown by triple-digits for seven quarters.
Mirum (MIRM) posts positive interim data from two phase IIb studies evaluating volixibat in patients with primary biliary cholangitis and primary sclerosing cholangitis. Stock rises.